Business Wire

MA-BATTERY-VENTURES

15.9.2021 13:02:10 CEST | Business Wire | Press release

Share
Battery Ventures Promotes Software Investor Jordan Welu to Partner

Battery Ventures, a global, technology-focused investment firm, promoted software investor Jordan Welu to the role of partner and announced a dozen other internal promotions as it expands the global reach of its venture-capital and private-equity businesses worldwide. Battery is currently investing its 13th family of funds, raised in early 2020 and capitalized at a combined $2 billion.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915005299/en/

Welu, who joined Battery in 2014, is a B2B-tech investor who focuses on growth-stage and buyout investments in areas such as infrastructure software, cybersecurity and financial technology. He is currently involved with Battery portfolio companies Alogent, DomainTools, Forest2Market, Learnosity and Plixer. Previously, he backed Concurrent Real-Time (acquired by Spectris) and Enviance (acquired by Cority).

Prior to Battery, Welu, who is based in Boston, worked in software corporate development and finance at companies including Rogue Wave Software, a former Battery portfolio company, and Webroot. Earlier in his career, he worked in investment banking and equity research. Jordan is a graduate of Georgetown University.

Battery also named two existing team members to the role of principal: Roland Anderson, based in Boston, and Satoshi Harris-Koizumi, based in New York. Both specialize in software investments. Anderson joined Battery in 2014 and Harris-Koizumi in 2012.

There were also six promotions to vice president. These include Danel Dayan and Courtney Chow in Menlo Park; Mike Hoeksema and Viraj Parmar in New York; Lauren Wedell in Boston; and Lior Mallul in Herzliya, Israel. In addition, Battery promoted three team members to associate. These include Maximilian Jessen and Matt Klineman, based in Boston, and Diego Liranzo in New York. Earlier this year, Battery promoted Antonia Heiss, based in London, to associate. Finally, the firm announced it has hired Jenny Kang as the firm’s vice president of talent for venture- and growth-stage companies. Previously, Kang was the head of go-to-market executive recruiting at Sequoia Capital.

“Jordan’s promotion to partner, following his work with Concurrent Real-Time and Enviance, is richly deserved, as are the promotions of all the new principals, vice presidents and associates,” said Jesse Feldman, a Battery general partner who helped make the original investment in Welu’s previous employer Rogue Wave Software. “More broadly, the moves highlight Battery’s longtime preference for promoting talent from within the firm as we seek out the most promising technology investments regardless of stage, sector or geography. We’re also very excited to add Jenny Kang to our team as we continue to offer more value-added services, including recruiting and talent assistance, to our portfolio companies.”

In the last 12 months, Battery has seen seven of its portfolio companies—Affirm, Coinbase, Confluent, JFrog, Olo, Sprinklr and Sumo Logic—stage initial public offerings. Since its founding in 1983 through June 30 of this year, Battery has funded 468 companies, not including seed investments, and realized 185 M&A events and 69 IPOs in total.

About Battery Ventures

Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, online marketplaces, healthcare IT and industrial technology. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from six strategic locations: Boston; San Francisco and Menlo Park, Calif.; Herzliya, Israel; London; and New York. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 18:26:00 CEST | Press release

Founding partners Beroe, Keelvar and Zip bring back the community-driven event with a practitioner-shaped agenda spanning real-world AI use and the future of procurement ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, fru

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye